Kinnate Raises $98m To Take Kinase Inhibitors Into The Clinic

The company’s next-generation kinase inhibitors are designed to target unaddressed mutations and overcome treatment resistance. Lead programs focus on BRAF Class II and III mutations and FGFR2/3.